Expression and Clinical Significance of CMTM6 in Nonsmall Cell Lung Cancer
Expression and Clinical Significance of CMTM6 in Nonsmall Cell Lung Cancer
复制标题
CMTM6在非小细胞肺癌中的表达及临床意义
DOI：
10.1089/dna.2020.5564
复制
发表时间：
2020-10-21
影响因子：
3.1
通讯作者：
Zhang, Kuanlin
中科院分区：
文献类型：
--
作者：
Hou, Xueyan;He, Sisi;Zhang, Kuanlin
趋化因子样因子（CKLF）样MARVEL跨膜结构域蛋白6（CMTM 6）是一种广泛表达的蛋白质，在程序性死亡配体1的稳定性中起关键作用。然而，CMTM 6在多种肿瘤病理组织中的表达尚不清楚。因此，本回顾性研究纳入了109例诊断为非小细胞肺癌（NSCLC）并接受手术切除的患者。免疫组化法检测CMTM 6在NSCLC组织中的表达，结果显示CMTM 6高表达60例（55.05%）。卡方检验显示CMTM 6在NSCLC中的表达与吸烟（p = 0.017）和分化程度（p = 0.029）显著相关。Kaplan-Meier生存分析提示，CMTM 6高表达与NSCLC患者的预后相关。单因素分析显示NSCLC患者的预后与T分期（p = 0.042）、淋巴结转移（p = 0.007）、转移（p = 0.009）、病理分化（p = 0.001）和CMTM 6表达水平（p < 0.001）有关。此外，多变量分析表明，CMTM 6是NSCLC患者的独立预后因素（p = 0.002）。CMTM 6表达可能成为NSCLC疾病监测和预后的生物标志物。
Chemokine-like factor (CKLF)-like MARVEL transmembrane domain containing protein 6 (CMTM6) is a ubiquitously expressed protein, which plays a critical role in the stability of programmed death-ligand 1. However, the expression of CMTM6 in a variety of cancer pathological tissues is not clear. Therefore, 109 patients who were diagnosed with nonsmall cell lung cancer (NSCLC) and underwent surgical resection were included in this retrospective study. The expression of CMTM6 in NSCLC patients' tissue samples were measured by immunohistochemistry and the results showed that 60 cases (55.05%) had high CMTM6 expression. The chi-square test showed that the expression of CMTM6 in NSCLC was significantly related to smoking (p = 0.017) and differentiation (p = 0.029). The Kaplan-Meier survival analysis suggested that the high expression of CMTM6 was associated with better prognosis of NSCLC patients. The univariate analysis revealed that the prognosis of NSCLC patients was correlated with T stage (p = 0.042), lymph node metastasis (p = 0.007), metastasis (p = 0.009), pathological differentiation (p = 0.001), and CMTM6 expression level (p < 0.001). In addition, multivariate analysis indicated that CMTM6 was an independent prognostic factor for NSCLC patients (p = 0.002). CMTM6 expression may have the potential to be a biomarker assisting in disease monitoring and prognosis in NSCLC.